U.S. Senate Debates How to Lower High Drug Prices
美國參議院辯論如何降低高昂藥價
Senate has been actively debating how to lower high prescription drug prices, an issue that deeply affects millions of families.
一個重要的里程碑是2022年的《降低通膨法案》(Inflation Reduction Act, IRA)，該法案允許聯邦醫療保險與特定藥價進行談判，並將胰島素的費用限制在每月35美元。
A major milestone was the 2022 Inflation Reduction Act (IRA), which allowed Medicare to negotiate certain drug prices and capped insulin costs at $35 per month.
儘管IRA邁出了重要的一步，但目前的焦點已轉向更具針對性的改革。
Lawmakers are currently scrutinizing Pharmacy Benefit Managers (PBMs)—the middlemen in the supply chain—who are accused of favoring expensive drugs to boost their own profits.
另一個熱門話題是「專利叢林」(patent thickets，ㄓㄨㄢㄌㄧˋㄘㄨㄥˊㄌㄧㄣˊ)，即公司利用過多的專利來阻止更便宜的學名藥進入市場。
Another hot topic is "patent thickets," where companies use excessive patents to block cheaper generic alternatives from entering the market.
核心的緊張關係在於平衡消費者成本與對藥物創新的需求。
The core tension lies in balancing lower consumer costs with the need for pharmaceutical innovation.
雖然民主黨人通常支持政府直接監管，但共和黨人傾向於強調基於市場的競爭與放鬆管制。
While Democrats often support direct government regulation, Republicans tend to emphasize market-based competition and deregulation.
儘管存在這些政治分歧，但在這一點上存在強烈的跨黨派共識：現行體系缺乏透明度。
Despite these political differences, there is strong bipartisan agreement on one thing: the current system lacks transparency.
隨著參議院委員會持續舉行聽證會，目標依然明確：在不阻礙未來藥物研發的前提下，讓民眾負擔得起救命藥物。
As Senate committees continue to hold hearings, the goal remains clear: making life-saving medications affordable without discouraging the research and development of future cures.
